评估接受 exenatide 治疗的非酒精性脂肪性肝病糖尿病患者的肝纤维化、FIB-4 和 APRI 评分。
Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease.
机构信息
Department of Endocrinology and Metabolism, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Sehit Omer Halisdemir Avenue, 06110, Ankara, Turkey.
Department of Gastroenterology, University of Health Sciences, Ankara Training and Research Hospital, Ankara, Turkey.
出版信息
Sci Rep. 2022 Jan 7;12(1):283. doi: 10.1038/s41598-021-04361-x.
There is a closely relationship between the development and progression of nonalcoholic fatty liver disease (NAFLD) or metabolic associated fatty liver disease (MAFLD) and obesity and diabetes. NAFLD fibrosis scores should be routinely used to rule out patients with advanced fibrosis. High scores may help identify patients at higher risk of all causes andliverrelated morbidity and mortality. The aim of this study was to investigate the association between exenatide and fibrosis scores. The effect of exenatide treatment on fibrosis scores was evaluated in type 2 diabetes mellitus (DM) patients with MAFLD. Evaluation was made of 50 patients with type 2 DM and MAFLD. The NFS, FIB4 and APRI scores were calculated before and after 6 months of treatment. After 6 months of exenatide treatment, the NFS and APRI scores were determined to have decreased significantly. Exenatide was observed to control blood glucose, reduce body weight and improve fibrosis scores in MAFLD patients with type 2 diabetes.
非酒精性脂肪性肝病（NAFLD）或代谢相关脂肪性肝病（MAFLD）的发生和进展与肥胖和糖尿病密切相关。NAFLD 纤维化评分应常规用于排除进展性纤维化患者。高分可能有助于识别所有原因和肝脏相关发病率和死亡率风险更高的患者。本研究旨在探讨 exenatide 与纤维化评分之间的关系。评估了 exenatide 治疗对 MAFLD 型 2 型糖尿病（DM）患者纤维化评分的影响。评估了 50 例 2 型 DM 和 MAFLD 患者。在治疗前和治疗 6 个月后计算 NFS、FIB4 和 APRI 评分。经过 6 个月的 exenatide 治疗，NFS 和 APRI 评分显著降低。观察到 exenatide 可控制血糖，减轻体重并改善 2 型糖尿病 MAFLD 患者的纤维化评分。
Zotero 插件